Cyclo Therapeutics, Inc. CYTH
0.72 0.00 (+0.00%)
At closeMar 26, 2025, 4:00 PM EDT
0.7206 Day range 0.7206
52-week range unavailable
- YTD
- +22.14%
- 1 year
- -49.61%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
businesswire.com CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
businesswire.com Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old) GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…
prnewswire.com SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
globenewswire.com Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Niemann-Pick disease -…
zacks.com Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.
prnewswire.com Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with…
prnewswire.com SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS…
accesswire.com STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS…
benzinga.com Rafael And Cyclo Therapeutics Have Agreed To Combine To Focus Trappsol Cyclo For Niemann-pick Disease Type C1 On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings…
businesswire.com Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…
zacks.com Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.33 per share a year ago.
businesswire.com Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…
businesswire.com Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…
businesswire.com Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…
businesswire.com Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…
businesswire.com Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…
businesswire.com Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
businesswire.com Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing…- benzinga.com Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.
businesswire.com Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative…
businesswire.com Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative…
businesswire.com APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied…- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
- benzinga.com Cyclo Therapeutics Ended The Quarter With ~$0.8M Of Cash. Subsequent To Quarter-End, The Company Generated Gross Proceeds Of $5M From The Sale Of Securities In Private Placements Of The Co's Securities Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end
benzinga.com Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket Gainers- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 76 companies set new 52-week lows.
- benzinga.com Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.
- benzinga.com Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
benzinga.com Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 574 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 351 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 209 companies set new 52-week lows.
benzinga.com 45 Biggest Movers From Yesterday Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter.- benzinga.com 61 Biggest Movers From Yesterday Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share.
- benzinga.com 38 Stocks Moving in Tuesday's Pre-Market Session Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares rose 108.4% to $6.48 in pre-market trading after the company announced an amendment under its exclusive U.S. commercialization agreement with…
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday, 596 companies set new 52-week highs.
- benzinga.com 101 Biggest Movers From Friday Gainers Atlantic American Corporation. (NASDAQ: AAME) shares surged 117.6% to close at $5.20 on Friday after surging over 5% on Thursday.
- benzinga.com 66 Stocks Moving In Friday's Mid-Day Session Gainers Atlantic American Corporation. (NASDAQ: AAME) shares jumped 279.5% to $9.07 after surging over 5% on Thursday.
benzinga.com Stocks That Hit 52-Week Highs On Thursday During Thursday's morning session, 255 companies made new 52-week highs.- benzinga.com 95 Biggest Movers From Yesterday Gainers
- benzinga.com 77 Biggest Movers From Yesterday Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday after gaining over 30% on Monday.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's session saw 466 companies set new 52-week highs.